On Thursday, the FDA granted approval to Pharming’s **[New Drug Name]**, potentially targeting the significant unmet need in **[Indication]**, though the commercial viability will ultimately depend on the ability to achieve cost-competitiveness compared to existing therapies. This strategic first-in-class authorization solidifies Pharming’s position in the **[Therapeutic Field]** but introduces volatility as investors weigh the stock's high valuation against crucial revenue milestones.